Pharmacokinetics of [14C]Ciclesonide After Oral and Intravenous Administration to Healthy Subjects
Purchase on Springer.com
$49.95 / €39.95 / £34.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Ciclesonide is a novel inhaled corticosteroid developed for the treatment of asthma.
To investigate the extent of oral absorption and bioavailability of ciclesonide referenced to an intravenous infusion. This information provides an estimate for the contribution of the swallowed fraction to systemic exposure to ciclesonide after oral inhalation.
In a randomised crossover study, six healthy male subjects (age range 19–40 years) received single doses of 6.9mg (oral administration) and 0.64mg (intravenous administration) of [14C]ciclesonide, separated by a washout period of at least 14 days. Total radioactivity was determined in whole blood, plasma, urine and faeces. Serum concentrations of ciclesonide and its major metabolite, the pharmacologically active desisobutyryl-ciclesonide (des-CIC), were determined in serum by high-performance liquid chromatography with tandem mass spectrometry detection.
After a 10-minute intravenous infusion, the mean half-life for total radioactivity was 45.2 hours. Elimination of des-CIC was fast with a mean elimination half-life of 3.5 hours. After oral administration, the mean half-life for total radioactivity was 27.5 hours. On the basis of a comparison of dose-normalised areas under the curve of total plasma radioactivity versus time, 24.5% of orally administered [14C]ciclesonide was absorbed. The parent compound ciclesonide was not detected in any of the serum samples after oral administration; serum concentrations of des-CIC were mostly near or below the lower limit of quantification. Thus, systemic bioavailability for des-CIC is <1% and the absolute bioavailability of ciclesonide is even less than this. [14C]Ciclesonide showed no retention in red blood cells. The mean cumulative excretion of total radioactivity was almost complete by 120 hours after oral and intravenous administration. Faecal excretion was the predominant route of excretion for total radioactivity after both routes of administration. Single oral and intravenous administration of ciclesonide was well tolerated.
Because of an almost complete first-pass metabolism, ciclesonide is undetectable in serum after oral administration. Thus, any ciclesonide swallowed after oral inhalation does not contribute to systemically available ciclesonide or to its active metabolite. Drug-related metabolites are excreted mainly via the faeces, and overall recovery of administered radioactivity is virtually complete after an extended sample collection period.
- Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995; 332: 868–75 CrossRef
- Beasley R, Crane J, Lai CK, et al. Prevalence and etiology of asthma. J Allergy Clin Immunol 2000; 105: S466–72 CrossRef
- Yang KD. Childhood asthma: aspects of global environment, genetics and management. Changgeng Yi Xue Za Zhi 2000; 23: 641–61
- Woolcock AJ, Bastiampillai SA, Marks GB, et al. The burden of asthma in Australia. Med J Aust 2001; 175: 141–5
- Blake KV. Drug treatment of airway inflammation in asthma. Pharmacotherapy 2001; 21: 3S–20S CrossRef
- Busse WW, Lemanske RFJ. Asthma. N Engl J Med 2001; 344: 350–62 CrossRef
- Stirling RG, Chung KF. Future treatments of allergic diseases and asthma. Br Med Bull 2000; 56: 1037–53 CrossRef
- Kumana CR, Kou M, Lauder IJ, et al. Increasing use of inhaled steroids associated with declining asthma mortality. J Asthma 2001; 38: 161–7 CrossRef
- Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992. Am Rev Respir Dis 1993; 148: S1–26
- van Staa TP, Leufkens HG, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001; 16: 581–8 CrossRef
- Leech JA, Hodder RV, Ooi DS, et al. Effects of short-term inhaled budesonide and beclomethasone dipropionate on serum osteocalcin in premenopausal women. Am Rev Respir Dis 1993; 148: 113–5
- Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997; 337: 8–14 CrossRef
- Taylor DA, Jensen MW, Kanabar V, et al. A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5′-monophosphate in asthmatic patients. Am J Respir Crit Care Med 1999; 160: 237–43
- Schmidt BM, Timmer W, Georgens AC, et al. The new topical steroid ciclesonide is effective in the treatment of allergic rhinitis. J Clin Pharmacol 1999; 39: 1062–9 CrossRef
- Kanniess F, Richter K, Bohme S, et al. Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma. Pulm Pharmacol Ther 2001; 14: 141–7 CrossRef
- Rohatagi S, Arya V, Zech K, et al. Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clin Pharmacol 2003; 43: 365–78 CrossRef
- Weinbrenner A, Hüneke D, Zschiesche M, et al. Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab 2002; 87: 2160–3 CrossRef
- Hall M, Peet CF, Boddington TKS, et al. Enzymology of the human hepatic metabolism of ciclesonide (B9207-015). Xenobiotic Metab Dispos 2000; Suppl. 15: 12
- Ryrfeldt A, Andersson P, Edsbacker S, et al. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis Suppl 1982; 122: 86–95
- Falcoz C, Mackie A, McDowall J. Oral bioavailability of fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1996; 41: 459P–60P
- Minto C, Li B, Tattam B, et al. Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation -intersubject variability in systemic absorption from the lung. Br J Clin Pharmacol 2000; 50: 116–24 CrossRef
- Rohatagi S, Appajosyula S, Derendorf H, et al. Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol 2004; 44: 37–47 CrossRef
- Pharmacokinetics of [14C]Ciclesonide After Oral and Intravenous Administration to Healthy Subjects
Volume 43, Issue 7 , pp 479-486
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors